<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579004</url>
  </required_header>
  <id_info>
    <org_study_id>2017-038</org_study_id>
    <nct_id>NCT03579004</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer</brief_title>
  <official_title>Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer: Single Arm Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mona Frolova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Russian Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate efficacy and safety of neoadjuvant chemotherapy followed
      by preoperative chemoradiotherapy in patients with resectable esophageal squamous cell
      carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted to evaluate efficacy and safety of neoadjuvant chemotherapy followed
      by preoperative chemoradiotherapy in patients with resectable esophageal squamous cell
      carcinoma.

      Patients with resectable esophageal squamous cell carcinoma receive 2 cycles of neoadjuvant
      chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750
      mg/m2/day continuous infusion, day 1-4 every 3 weeks). Patients who do not progress with
      distant metastases start preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20
      mg/m2 weekly + radiotherapy 44 Gy for 4 weeks).

      4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy
      irrespectively of objective response.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">July 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Disease free survival will be calculated from the start of the treatment to the disease progression or death of any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival will be calculated from the start of the treatment to the death of any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate according to RECIST 1.1</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response rate will be evaluated separately after chemotherapy and chemoradiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity will be assessed separately after chemotherapy, chemoradiotherapy and surgery according NCI CTC AE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate following chemoradiotherapy</measure>
    <time_frame>24 months</time_frame>
    <description>Pathological complete response rate following chemoradiotherapy will be assessed in resected patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Concurrent Chemoradiotherapy</condition>
  <arm_group>
    <arm_group_label>Trimodality approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).
4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy</description>
    <arm_group_label>Trimodality approach</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy</description>
    <arm_group_label>Trimodality approach</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil is used in two cycles of neoadjuvant chemotherapy</description>
    <arm_group_label>Trimodality approach</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiotherapy</intervention_name>
    <description>Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.</description>
    <arm_group_label>Trimodality approach</arm_group_label>
    <other_name>chemoradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ivor Lewis esophagogastrectomy</intervention_name>
    <description>Open Ivor Lewis esophagogastrectomy</description>
    <arm_group_label>Trimodality approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18-75

          2. Histologically or cytologically confirmed resectable squamous-cell Tumor (T)1-2 node
             (N)+, T3N0-3 esophageal cancer. Inclusion of patients with morphologically confirmed
             and potentially resectable supraclavicular lymphnodes (unilateral, less than 1,5 cm in
             short axis) is allowed

          3. No prior antineoplastic treatment

          4. Eastern Cooperative Oncology Group (ECOG) status 0-2

          5. Adequate organ function, evidenced by laboratory results with no contraindications to
             chemotherapy

               -  absolute neutrophil count ≥ 1,500 х109/l

               -  thrombocytes ≥ 100 х 109/l

               -  hemoglobin ≥ 90 mg/l

               -  creatinine &lt; 115 µmol/л or creatinine clearance ≥ 55 ml/min

               -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt; 2.5 x upper
                  limit of normal (ULN)

               -  alkaline phosphatase (ALP) &gt; 5 x ULN

               -  bilirubin &gt; 1,5 х ULN

          6. Women of childbearing potential must have negative pregnancy test, performed 7 days
             prior to initial treatment

          7. Patients must follow appropriate contraception rules during whole treatment period

          8. Decrease of body weight must not be more than 20% in last 6 months

        Exclusion Criteria:

          1. Presence of distant metastases except for metastatic supraclavicular lymphnodes;

          2. Bulky (&gt;3 cm) regional lymphnodes metastases;

          3. Cervical esophageal cancer;

          4. Presence of tumor fistula;

          5. Prior malignant tumor, except for proper treated skin basal cell carcinoma and in situ
             cervical cancer;

          6. Active infectious diseases and concomitant diseases that can affect treatment
             tolerability, surgery and other study procedures;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexey Tryakin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexey Tryakin, MD, PhD</last_name>
    <phone>4993249259</phone>
    <phone_ext>+7</phone_ext>
    <email>atryakin@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilya Pokataev, MD, PhD</last_name>
    <phone>4993241219</phone>
    <phone_ext>+7</phone_ext>
    <email>pokia@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alexey Tryakin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Tryakin, MD, PhD</last_name>
      <phone>4993249259</phone>
      <phone_ext>+7</phone_ext>
      <email>atryakin@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Cancer Research Center named after N.N.Blokhin RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Tryakin, PhD</last_name>
      <phone>+74993249259</phone>
      <email>atryakin@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Ilya Pokataev</last_name>
      <phone>+74993241219</phone>
      <email>pokia@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Alexey Tryakin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>July 4, 2018</last_update_submitted>
  <last_update_submitted_qc>July 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mona Frolova</investigator_full_name>
    <investigator_title>Senior Staff Member</investigator_title>
  </responsible_party>
  <keyword>esophageal squamous cell carcinoma</keyword>
  <keyword>preoperative chemoradiotherapy</keyword>
  <keyword>preoperative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

